Stryker to acquire Inari Medical for $4.9 billion, enhancing its peripheral vascular disease portfolio.
Read more
Amgen's IMDYLLTRA® receives UK approval for third-line treatment of extensive-stage Small Cell Lung Cancer.
Read more
Qu Biologics' QBECO SSI shows promise in reducing liver fat, inflammation, and fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
Read more
Tempest's amezalpat receives FDA Orphan Drug Designation for Hepatocellular Carcinoma treatment.
Read more
FDA grants priority review for CUTX-101 NDA for Menkes Disease treatment, with action date set for June 30, 2025.
Read more
China approves first stem cell therapy for acute graft-versus-host disease and new HIV drug lenacapavir.
Read more
CAR-T cell therapy market expands with new FDA approvals and late-stage trials targeting cancer treatment.
Read more
DiaCarta's blood test reduces colonoscopy need by 33% in FIT-positive Colorectal Cancer screening.
Read more
Novo Holdings invests €90M in Orbis Medicines for oral macrocycle drug development.
Read more
Oculis' OCS-05 shows positive Phase 2 trial results for Acute Optic Neuritis, meeting safety and efficacy endpoints.
Read more
TEPOXX approved in Japan for Orthopoxvirus treatment, including Smallpox, marking a significant regulatory milestone.
Read more
Genetic testing identifies drug resistance in Candida auris, improving treatment for this multidrug-resistant fungus.
Read more
Care Access offers no-cost screenings in Aurora for cardiovascular and kidney health, focusing on lipoprotein(a) risk awareness.
Read more
BeiGene acquires global rights for DualityBio's antibody-drug conjugate developed with Nona Biosciences.
Read more
CathWorks completes enrollment for ALL-RISE trial, evaluating FFRangio in Coronary Artery Disease treatment.
Read more
CHOP develops ATLAS-seq to enhance T cell receptor identification for cancer immunotherapy.
Read more
FDA grants priority review to CUTX-101 for Menkes Disease, potential first approved treatment.
Read more
Orbis Medicines raises EUR 90M to develop oral macrocycle drugs, appoints Morten Graugaard as CEO.
Read more
MilliporeSigma acquires HUB Organoids to enhance drug development with advanced organoid technology.
Read more
Waud Capital acquires Mopec Group to enhance pathology solutions and drive growth in healthcare markets.
Read more
ACELYRIN to present Phase 2 data and Phase 3 design for lonigutamab in Thyroid Eye Disease.
Read more
WuXi Biologics partners with Candid Therapeutics on trispecific T-cell engager for autoimmune diseases.
Read more
FDA approved 50 new molecular entities in 2024, marking the sixth year with 50+ approvals since 1985.
Read more
Sterilization equipment market projected to reach $26.77 billion by 2031, driven by pharmaceutical and biotechnology demand.
Read more
Renovaro to acquire Predictive Oncology, enhancing AI-driven cancer diagnostics and drug discovery capabilities.
Read more
